Compare ZWS & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZWS | ICLR |
|---|---|---|
| Founded | 1900 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.3B |
| IPO Year | 2008 | 2001 |
| Metric | ZWS | ICLR |
|---|---|---|
| Price | $51.29 | $164.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $53.67 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 1.0M | 825.4K |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,530,500,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $5.13 | N/A |
| P/E Ratio | $146.91 | ★ $12.91 |
| Revenue Growth | ★ 19.40 | N/A |
| 52 Week Low | $43.06 | $66.57 |
| 52 Week High | $55.00 | $203.91 |
| Indicator | ZWS | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 52.15 |
| Support Level | $49.23 | $157.06 |
| Resistance Level | $51.65 | $188.49 |
| Average True Range (ATR) | 1.48 | 7.87 |
| MACD | 0.26 | -1.39 |
| Stochastic Oscillator | 55.07 | 42.24 |
Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.